AU2022220512A1 - Bioactive substance conjugate, preparation method therefor and use thereof - Google Patents
Bioactive substance conjugate, preparation method therefor and use thereof Download PDFInfo
- Publication number
- AU2022220512A1 AU2022220512A1 AU2022220512A AU2022220512A AU2022220512A1 AU 2022220512 A1 AU2022220512 A1 AU 2022220512A1 AU 2022220512 A AU2022220512 A AU 2022220512A AU 2022220512 A AU2022220512 A AU 2022220512A AU 2022220512 A1 AU2022220512 A1 AU 2022220512A1
- Authority
- AU
- Australia
- Prior art keywords
- seq
- sequence
- antibody
- antigen
- attached
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/545—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68037—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a camptothecin [CPT] or derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6875—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin
- A61K47/6879—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin the immunoglobulin having two or more different antigen-binding sites, e.g. bispecific or multispecific immunoglobulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
- A61K49/0058—Antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Cell Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2026206227A AU2026206227A1 (en) | 2021-02-09 | 2026-07-17 | Bioactive Substance Conjugate, Preparation Method Therefor And Use Thereof |
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110178136.1 | 2021-02-09 | ||
| CN202110178136 | 2021-02-09 | ||
| CN202110340806 | 2021-03-30 | ||
| CN202110340806.5 | 2021-03-30 | ||
| CN202110825932.X | 2021-07-21 | ||
| CN202110825922 | 2021-07-21 | ||
| CN202110825922.6 | 2021-07-21 | ||
| CN202110825932 | 2021-07-21 | ||
| CN202110825906 | 2021-07-21 | ||
| CN202110825906.7 | 2021-07-21 | ||
| PCT/CN2022/073822 WO2022170971A1 (zh) | 2021-02-09 | 2022-01-25 | 生物活性物偶联物及其制备方法和用途 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2026206227A Division AU2026206227A1 (en) | 2021-02-09 | 2026-07-17 | Bioactive Substance Conjugate, Preparation Method Therefor And Use Thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2022220512A1 true AU2022220512A1 (en) | 2023-07-13 |
| AU2022220512A9 AU2022220512A9 (en) | 2024-10-24 |
Family
ID=82838257
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2022220512A Pending AU2022220512A1 (en) | 2021-02-09 | 2022-01-25 | Bioactive substance conjugate, preparation method therefor and use thereof |
| AU2026206227A Pending AU2026206227A1 (en) | 2021-02-09 | 2026-07-17 | Bioactive Substance Conjugate, Preparation Method Therefor And Use Thereof |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2026206227A Pending AU2026206227A1 (en) | 2021-02-09 | 2026-07-17 | Bioactive Substance Conjugate, Preparation Method Therefor And Use Thereof |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20240108745A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4257154A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024508081A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230145038A (cg-RX-API-DMAC7.html) |
| CN (7) | CN120093941A (cg-RX-API-DMAC7.html) |
| AU (2) | AU2022220512A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3206117A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL304804A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2023008895A (cg-RX-API-DMAC7.html) |
| TW (1) | TW202241521A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022170971A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (69)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20240031235A (ko) * | 2021-05-27 | 2024-03-07 | 자임워크스 비씨 인코포레이티드 | 캄프토테신 유사체, 접합체 및 사용 방법 |
| JP2024532768A (ja) * | 2021-08-19 | 2024-09-10 | ハイナン シムセレ ザイミン ファーマシューティカル カンパニー リミテッド | カンプトテシン誘導体、その薬物組成物およびその応用 |
| CA3233254A1 (en) | 2021-09-27 | 2023-03-30 | Evopoint Biosciences Co., Ltd. | Antibody, antibody-drug conjugate thereof and use thereof |
| KR20240137076A (ko) * | 2022-01-25 | 2024-09-19 | 메디링크 테라퓨틱스 (쑤저우) 컴퍼니, 리미티드 | Her3에 대한 항체, 접합체 및 이의 용도 |
| WO2023143208A1 (zh) * | 2022-01-26 | 2023-08-03 | 苏州宜联生物医药有限公司 | 一种药物连接体偶联物的制备方法 |
| KR20240150773A (ko) | 2022-02-24 | 2024-10-16 | 에보포인트 바이오사이언시스 컴퍼니 리미티드 | 항체 및 약물 접합체 및 이의 용도 |
| KR20240162575A (ko) | 2022-03-25 | 2024-11-15 | 자임워크스 비씨 인코포레이티드 | 엽산 수용체 알파를 표적화하는 항체-약물 접합체 및 사용 방법 |
| KR20230149752A (ko) * | 2022-04-20 | 2023-10-27 | 주식회사 피노바이오 | Ddx5 단백질에 결합하는 캄토테신 유도체 및 이의 프로드럭 |
| JP2025515988A (ja) * | 2022-05-13 | 2025-05-23 | シチュアン ケルン-バイオテック バイオファーマシューティカル カンパニー リミテッド | カンプトテシン化合物、その調製方法及びその使用 |
| EP4527415A1 (en) | 2022-05-18 | 2025-03-26 | Medilink Therapeutics (Suzhou) Co., Ltd. | Antibody-drug conjugate containing protein degradation agent bioactive compound, method for preparing same, and use thereof |
| AU2023278370A1 (en) | 2022-05-30 | 2025-01-09 | Medilink Therapeutics (Suzhou) Co., Ltd. | Preparation method for drug linker conjugate and intermediate thereof |
| KR20240008280A (ko) * | 2022-07-11 | 2024-01-18 | 주식회사 피노바이오 | Ddx5 단백질에 결합하는 캄토테신 유도체 및 이의 프로드럭 |
| CN119486763A (zh) * | 2022-07-14 | 2025-02-18 | 苏州宜联生物医药有限公司 | 抗体药物偶联物及其制备方法和用途 |
| JP2025527263A (ja) * | 2022-08-02 | 2025-08-20 | ノナ・バイオサイエンシズ(スーチョウ)カンパニー,リミテッド | Msln抗体-薬物コンジュゲート |
| KR20240035370A (ko) * | 2022-09-08 | 2024-03-15 | 주식회사 피노바이오 | 신규 캄토테신 유도체 및 이를 포함하는 운반체-약물 접합체 |
| CN121064211A (zh) * | 2022-09-09 | 2025-12-05 | 杭州爱科瑞思生物医药有限公司 | 喜树碱-7-乙基胺衍生物及其制备方法和应用 |
| KR20250079213A (ko) | 2022-10-09 | 2025-06-04 | 라노바 메디신즈 리미티드 | 화합물, 조성물 및 방법 |
| WO2024114318A1 (zh) * | 2022-11-29 | 2024-06-06 | 四川科伦博泰生物医药股份有限公司 | 药物连接子化合物及其制备方法和用途 |
| AU2023389998A1 (en) * | 2022-12-07 | 2025-06-12 | Merck Sharp & Dohme Llc | Process for making antibody-drug conjugates |
| CN120513102A (zh) * | 2022-12-22 | 2025-08-19 | 苏州宜联生物医药有限公司 | 一种抗体药物偶联物及其制备方法和用途 |
| JP7890426B2 (ja) | 2022-12-23 | 2026-07-15 | メディリンク セラピューティクス(スーチョウ)カンパニー,リミティド | 抗cMet抗体、抗体薬物複合体、及びその調製方法と使用 |
| CN115881311B (zh) * | 2022-12-23 | 2023-10-27 | 南京普恩瑞生物科技有限公司 | 一种利用肿瘤活组织模拟临床试验进行抗体偶联药物适应症筛选的方法 |
| CN116726192B (zh) * | 2022-12-29 | 2025-11-07 | 杭州爱科瑞思生物医药有限公司 | N-烷氧烷基取代的喜树碱衍生物的抗体偶联药物 |
| CN116712562A (zh) * | 2022-12-29 | 2023-09-08 | 杭州爱科瑞思生物医药有限公司 | N-叠氮烷基取代的喜树碱衍生物的抗体偶联药物 |
| TW202430225A (zh) * | 2022-12-29 | 2024-08-01 | 英屬開曼群島商百濟神州有限公司 | B7h3抗體藥物共軛物 |
| CN116870187A (zh) * | 2022-12-29 | 2023-10-13 | 杭州爱科瑞思生物医药有限公司 | N-氧杂环烷基取代的喜树碱衍生物的抗体偶联药物 |
| CN116712563A (zh) * | 2022-12-29 | 2023-09-08 | 杭州爱科瑞思生物医药有限公司 | N-卤代烷基取代的喜树碱衍生物的抗体偶联药物 |
| EP4653018A1 (en) | 2023-01-18 | 2025-11-26 | Medilink Therapeutics (Suzhou) Co., Ltd. | Antibody drug conjugate as well as preparation method therefor and use thereof |
| JP2026511515A (ja) * | 2023-03-23 | 2026-04-14 | ビーワン メディシンズ ワン ゲーエムベーハー | 生体活性コンジュゲートならびにその調製方法及びその使用 |
| EP4688787A1 (en) * | 2023-04-07 | 2026-02-11 | Innovent Biologics (Suzhou) Co., Ltd. | Antibody-drug conjugates of camptothecin derivatives and uses thereof |
| CN120826405A (zh) * | 2023-05-04 | 2025-10-21 | 四川科伦博泰生物医药股份有限公司 | 具有靶向作用的偶联物及其制备方法和用途 |
| KR20260007619A (ko) * | 2023-05-09 | 2026-01-14 | 상하이 헨리우스 바이오테크, 인크. | 항-pdl1 항체-약물 접합체 및 응용 |
| CN121263211A (zh) * | 2023-05-09 | 2026-01-02 | 上海复宏汉霖生物技术股份有限公司 | 一种抗表皮生长因子受体(egfr)抗体-药物偶联物及其应用 |
| WO2024235136A1 (zh) * | 2023-05-12 | 2024-11-21 | 四川科伦博泰生物医药股份有限公司 | 杂环类化合物及其制备方法和用途 |
| EP4710946A1 (en) | 2023-05-12 | 2026-03-18 | Medilink Therapeutics (Suzhou) Co., Ltd. | Multi-projectile antibody-drug conjugate, and preparation method therefor and use thereof |
| CN120981250A (zh) * | 2023-05-12 | 2025-11-18 | 四川科伦博泰生物医药股份有限公司 | 具有生物活性的化合物及其制备方法和用途 |
| CN120981249A (zh) * | 2023-05-12 | 2025-11-18 | 四川科伦博泰生物医药股份有限公司 | 多环化合物及其制备方法和用途 |
| AU2024302681A1 (en) * | 2023-06-13 | 2026-01-15 | Chengdu Brilliant Pharmaceutical Co., Ltd. | Camptothecin derivative for treating or preventing cancer, and antibody-drug conjugate thereof |
| EP4748842A1 (en) * | 2023-07-20 | 2026-05-27 | Shanghai Pharmaceuticals Holding Co., Ltd. | Camptothecin compound, antibody drug conjugate, and preparation method therefor and use thereof |
| CN122121899A (zh) | 2023-08-18 | 2026-05-29 | 康诺亚生物医药科技有限公司 | 五环类活性化合物及其偶联物和用途 |
| WO2025048588A1 (ko) * | 2023-08-31 | 2025-03-06 | 주식회사 피노바이오 | 신규 캄토테신 유도체 및 이를 포함하는 항체-약물 접합체 |
| CN121752297A (zh) * | 2023-09-01 | 2026-03-27 | 四川科伦博泰生物医药股份有限公司 | 抗体-药物缀合物及其制备方法和用途 |
| CN121909048A (zh) | 2023-09-19 | 2026-04-21 | 苏州宜联生物医药有限公司 | 抗b7h3抗体药物偶联物在制备治疗鼻咽癌和/或肺淋巴上皮瘤样癌的药物中的用途 |
| CN122295130A (zh) * | 2023-10-19 | 2026-06-26 | 赛特瑞恩股份有限公司 | 包含喜树碱衍生物的抗c-met抗体-药物缀合物 |
| KR20250057677A (ko) * | 2023-10-19 | 2025-04-29 | (주)셀트리온 | 캄프토테신 유도체를 포함하는 항-Nectin-4 항체-약물 접합체 |
| KR20260115591A (ko) * | 2023-10-19 | 2026-07-24 | 유노벨(상하이) 바이오파마 씨오 엘티디 | 폴리펩타이드, 생리활성 접합체, 이의 제조방법 및 용도 |
| CN122295131A (zh) * | 2023-10-19 | 2026-06-26 | 赛特瑞恩股份有限公司 | 包含喜树碱衍生物的抗组织因子抗体-药物缀合物 |
| CN119454937A (zh) | 2023-11-13 | 2025-02-18 | 苏州宜联生物医药有限公司 | 抗b7h3抗体-药物偶联物治疗癌症的方法 |
| CN122374343A (zh) | 2023-11-30 | 2026-07-10 | 江苏康宁杰瑞生物制药有限公司 | 包含pd-l1结合分子与双特异性抗体-药物偶联物的组合物及其用途 |
| TW202532100A (zh) * | 2023-12-22 | 2025-08-16 | 大陸商信達生物製藥(蘇州)有限公司 | 靶向b7h3和egfr的雙特異性抗體-藥物偶聯物及其應用 |
| AU2024415931A1 (en) | 2023-12-27 | 2026-07-16 | Jiangsu Alphamab Biopharmaceuticals Co., Ltd. | Multi-specific antibody targeting her3 and trop2 and conjugate thereof |
| US20250213712A1 (en) * | 2023-12-27 | 2025-07-03 | Intocell, Inc. | Antibody drug conjugates comprising camptothecin derivatives and uses thereof |
| WO2025167900A1 (zh) * | 2024-02-06 | 2025-08-14 | 上海齐鲁制药研究中心有限公司 | 澳瑞他汀类抗体药物偶联物及其制备方法和应用 |
| TW202543685A (zh) * | 2024-03-04 | 2025-11-16 | 大陸商蘇州宜聯生物醫藥有限公司 | 抗體藥物偶聯物及其製備方法和用途 |
| WO2025214403A1 (zh) * | 2024-04-12 | 2025-10-16 | 四川科伦博泰生物医药股份有限公司 | 抗体药物偶联物、组合物及其用途和方法 |
| WO2025230926A1 (en) * | 2024-04-29 | 2025-11-06 | Obi Pharma, Inc. | Improved linker-payloads for antibody conjugation, pharmaceutical compositions and applications thereof |
| WO2025232845A1 (zh) * | 2024-05-10 | 2025-11-13 | 四川科伦博泰生物医药股份有限公司 | 具有靶向作用的偶联物及其制备方法和用途 |
| WO2025232843A1 (zh) * | 2024-05-10 | 2025-11-13 | 四川科伦博泰生物医药股份有限公司 | 稠环类化合物及其制备方法和用途 |
| TW202612739A (zh) | 2024-05-16 | 2026-04-01 | 日商第一三共股份有限公司 | 抗b7-h3抗體-藥物結合物與雄性素受體傳訊抑制劑之組合 |
| TW202547557A (zh) * | 2024-05-30 | 2025-12-16 | 德商拜恩技術股份公司 | 抗體藥物結合物之新用途 |
| EP4766727A1 (en) | 2024-06-14 | 2026-07-01 | Biontech SE | Polytherapy for the treatment of cancer |
| WO2025256761A1 (en) | 2024-06-14 | 2025-12-18 | BioNTech SE | Combination therapy for cancer treatment |
| WO2026046075A1 (zh) * | 2024-08-24 | 2026-03-05 | 苏州宜联生物医药有限公司 | 抗b7h3抗体药物偶联物在制备小细胞肺癌(sclc)药物中的用途 |
| WO2026046060A1 (zh) * | 2024-08-24 | 2026-03-05 | 苏州宜联生物医药有限公司 | 抗b7h3抗体药物偶联物用于治疗癌症的方法 |
| WO2026085745A1 (en) * | 2024-10-23 | 2026-04-30 | Zai Lab (Shanghai) Co., Ltd. | Dosing regimens of antibody-drug conjugate targeting delta-like ligand 3 for treatment of neuroendocrine neoplasms |
| WO2026086850A1 (en) * | 2024-10-23 | 2026-04-30 | Zai Lab (Shanghai) Co., Ltd. | Dosing regimens of antibody-drug conjugate targeting delta-like ligand 3 for treatment of neuroendocrine neoplasms |
| WO2026130566A1 (zh) * | 2024-12-20 | 2026-06-25 | 上海复宏汉霖生物技术股份有限公司 | 一种配体-药物偶联物及其制备方法和应用 |
| WO2026149557A1 (zh) * | 2025-01-10 | 2026-07-16 | 正大天晴药业集团股份有限公司 | 新型亲水性连接体及其药物连接体、蛋白质偶联药物、药物组合物和用途 |
| WO2026165269A1 (en) * | 2025-01-29 | 2026-08-06 | Sutro Biopharma, Inc. | Anti-b7-h3 antibodies, compositions comprising anti-b7-h3 antibodies and methods of making and using anti- b7-h3 antibodies |
Family Cites Families (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL154598B (nl) | 1970-11-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking. |
| US3817837A (en) | 1971-05-14 | 1974-06-18 | Syva Corp | Enzyme amplification assay |
| US3939350A (en) | 1974-04-29 | 1976-02-17 | Board Of Trustees Of The Leland Stanford Junior University | Fluorescent immunoassay employing total reflection for activation |
| US3996345A (en) | 1974-08-12 | 1976-12-07 | Syva Company | Fluorescence quenching with immunological pairs in immunoassays |
| US4275149A (en) | 1978-11-24 | 1981-06-23 | Syva Company | Macromolecular environment control in specific receptor assays |
| US4277437A (en) | 1978-04-05 | 1981-07-07 | Syva Company | Kit for carrying out chemically induced fluorescence immunoassay |
| US4366241A (en) | 1980-08-07 | 1982-12-28 | Syva Company | Concentrating zone method in heterogeneous immunoassays |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| JP2003512819A (ja) | 1999-09-03 | 2003-04-08 | ヒューマン ジノーム サイエンシーズ, インコーポレイテッド | B7様ポリヌクレオチド、ポリペプチドおよび抗体 |
| WO2002010187A1 (en) | 2000-07-27 | 2002-02-07 | Mayo Foundation For Medical Education And Research | B7-h3 and b7-h4, novel immunoregulatory molecules |
| US20050002935A1 (en) | 2003-04-17 | 2005-01-06 | Vincent Ling | Use of B7-H3 as an immunoregulatory agent |
| UA90480C2 (uk) | 2004-07-22 | 2010-05-11 | Джэнэнтэк, Инк. | Фармацевтична композиція, що має протипухлинну активність, яка включає антитіло до her2 |
| CN101104639A (zh) | 2006-07-10 | 2008-01-16 | 苏州大学 | 抗人b7-h3单克隆抗体的制备及其应用 |
| EP2094307A4 (en) | 2006-11-08 | 2015-08-26 | Macrogenics West Inc | TES7 AND THEREO BINDING ANTIBODIES |
| EP2443125B1 (en) * | 2009-06-17 | 2014-11-26 | Threshold Pharmaceuticals, Inc. | Camptothecin derivatives |
| PH12012501751A1 (en) | 2010-03-04 | 2012-11-12 | Macrogenics Inc | Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof |
| DK2542256T3 (da) | 2010-03-04 | 2019-08-26 | Macrogenics Inc | Antistoffer reagerende med b7-h3, immunologisk aktive fragmenter deraf og anvendelser deraf |
| US9932403B2 (en) | 2010-05-20 | 2018-04-03 | Ablynx Nv | Biological materials related to HER3 |
| CA2813796C (en) | 2010-10-18 | 2019-01-15 | Mediapharma S.R.L. | Erbb3 binding antibody |
| EP2703486B1 (en) | 2011-04-25 | 2018-03-07 | Daiichi Sankyo Company, Limited | Anti-b7-h3 antibody |
| US10195288B2 (en) | 2012-10-11 | 2019-02-05 | Daiichi Sankyo Company, Limited | Antibody-drug conjugate |
| CN103319599B (zh) | 2013-05-27 | 2015-02-18 | 上海交联药物研发有限公司 | 一种抗人ErbB2抗体—美登木素偶联物及其应用 |
| EP3100734A4 (en) * | 2014-01-28 | 2017-08-09 | Zhou, Wenqiang | Use of camptothecin derivative in preparing pharmaceutical used for treating multiple myeloma |
| TWI871999B (zh) * | 2014-04-10 | 2025-02-01 | 日商第一三共股份有限公司 | 抗her3抗體-藥物結合物 |
| EP3149040A1 (en) | 2014-05-29 | 2017-04-05 | Spring Bioscience Corporation | Anti-b7-h3 antibodies and diagnostic uses thereof |
| KR102485788B1 (ko) | 2014-08-27 | 2023-01-09 | 메모리얼 슬로안 케터링 캔서 센터 | 항체, 조성물 및 용도 |
| JP6613304B2 (ja) | 2014-09-17 | 2019-12-04 | ザ ユナイテッド ステイツ オブ アメリカ, アズ リプレゼンテッド バイ ザ セクレタリー, デパートメント オブ ヘルス アンド ヒューマン サービシーズ | 抗cd276抗体(b7h3) |
| US9963509B2 (en) | 2014-12-23 | 2018-05-08 | Full Spectrum Genetics, Inc. | Anti-B7H3 binding compounds and uses thereof |
| US10865245B2 (en) | 2014-12-23 | 2020-12-15 | Full Spectrum Genetics, Inc. | Anti-B7H3 binding compounds and uses thereof |
| CN109069633A (zh) | 2016-04-15 | 2018-12-21 | 宏观基因有限公司 | 新颖的b7-h3-结合分子、其抗体药物缀合物及其使用方法 |
| RS61828B1 (sr) * | 2016-06-08 | 2021-06-30 | Abbvie Inc | Anti-b7-h3 antitela i antitelske konjugacije lekova |
| CN109641962A (zh) * | 2016-06-08 | 2019-04-16 | 艾伯维公司 | 抗b7-h3抗体和抗体药物偶联物 |
| JP2019526529A (ja) * | 2016-06-08 | 2019-09-19 | アッヴィ・インコーポレイテッド | 抗b7−h3抗体及び抗体薬物コンジュゲート |
| CA3056474A1 (en) * | 2017-03-31 | 2018-10-04 | Jiangsu Hengrui Medicine Co., Ltd. | B7-h3 antibody, antigen-binding fragment thereof and medical use thereof |
| JP2020520382A (ja) | 2017-05-12 | 2020-07-09 | メモリアル スローン ケタリング キャンサー センター | 中枢神経系におけるがんを処置するための抗b7h3抗体の使用 |
| CN119219654A (zh) * | 2017-12-15 | 2024-12-31 | 四川科伦博泰生物医药股份有限公司 | 生物活性物偶联物及其制备方法和用途 |
| CN111542324B (zh) * | 2018-02-11 | 2023-09-12 | 四川科伦博泰生物医药股份有限公司 | 细胞毒性剂及其偶联物、其制备方法及用途 |
| CN111936169A (zh) * | 2018-04-06 | 2020-11-13 | 西雅图遗传学公司 | 喜树碱肽缀合物 |
| WO2019225787A1 (ko) | 2018-05-24 | 2019-11-28 | 에이비엘바이오 주식회사 | 항-b7-h3 항체 및 그 용도 |
| TWI920652B (zh) * | 2018-06-07 | 2026-04-01 | 美商思進公司 | 喜樹鹼結合物 |
| WO2020033702A1 (en) * | 2018-08-08 | 2020-02-13 | Dragonfly Therapeutics, Inc. | Proteins binding nkg2d, cd16 and a tumor-associated antigen |
| US12274759B2 (en) | 2018-08-23 | 2025-04-15 | Regents Of The University Of Minnesota | Affibody proteins specific for B7-H3 (CD276) |
| EP3844191A4 (en) | 2018-08-31 | 2022-06-15 | Seattle Children's Hospital (DBA Seattle Children's Research Institute) | METHODS AND COMPOSITIONS USING CHIMERIC B7H3 ANTIGEN RECEPTORS |
| JP7408646B2 (ja) | 2018-09-30 | 2024-01-05 | ジエンス ハンソー ファーマスーティカル グループ カンパニー リミテッド | 抗-b7h3抗体-エキサテカンアナログコンジュゲート及びその医薬用途 |
| CN110305213B (zh) | 2018-11-09 | 2023-03-10 | 泰州复旦张江药业有限公司 | 一种抗b7-h3抗体及其制备方法、其偶联物和应用 |
| CN113330034A (zh) | 2018-11-16 | 2021-08-31 | 阿尔伯特爱因斯坦医学院 | 针对B7-H3的IgV结构域的单克隆抗体及其用途 |
| EP3883970A4 (en) | 2018-11-22 | 2022-03-30 | Suzhou Kanova Biopharmaceutical Co., Ltd. | ANTI-B7-H3 ANTIBODIES |
| WO2020140094A1 (en) | 2018-12-27 | 2020-07-02 | Gigagen, Inc. | Anti-b7-h3 binding proteins and methods of use thereof |
| US20220089752A1 (en) | 2019-01-14 | 2022-03-24 | The Regents Of The University Of California | Compositions and methods for modulating cellular internalization |
| CN109851673B (zh) | 2019-01-22 | 2023-07-25 | 苏州旭光科星抗体生物科技有限公司 | 一种抗人b7-h3单克隆抗体的制备方法及其免疫组化检测方法及其应用及其试剂盒 |
| RS64961B1 (sr) * | 2019-04-26 | 2024-01-31 | Immunogen Inc | Derivati kamptotecina |
| KR102732027B1 (ko) | 2019-07-09 | 2024-11-20 | 주식회사 와이바이오로직스 | B7-h3(cd276)에 특이적으로 결합하는 항체 및 그의 용도 |
| WO2021021543A1 (en) | 2019-07-26 | 2021-02-04 | Corbus Pharmaceuticals, Inc. | Compositions and methods for attenuating side effects of immune checkpoint inhibitor therapy |
| CN111454357B (zh) | 2019-08-14 | 2022-03-15 | 康诺亚生物医药科技(成都)有限公司 | 一种含有抗体的肿瘤治疗剂的开发和应用 |
| CN110642948B (zh) | 2019-10-09 | 2021-06-29 | 达石药业(广东)有限公司 | B7-h3纳米抗体、其制备方法及用途 |
| CN110684790A (zh) | 2019-10-31 | 2020-01-14 | 山东兴瑞生物科技有限公司 | 抗b7-h3嵌合抗原受体的编码基因、制备方法、具有该基因的质粒、免疫细胞及其应用 |
| MX2022010176A (es) | 2020-02-20 | 2023-01-16 | Win Therapeutics Inc | Moléculas de unión biespecíficas a gd2 y b7h2 y métodos de uso. |
| CN111662384B (zh) | 2020-06-30 | 2021-04-09 | 广州百暨基因科技有限公司 | 抗b7h3抗体及其应用 |
| CN113480668A (zh) | 2020-12-14 | 2021-10-08 | 广州百暨基因科技有限公司 | 抗b7h3嵌合抗原受体及其应用 |
-
2022
- 2022-01-25 CN CN202510075421.9A patent/CN120093941A/zh active Pending
- 2022-01-25 CN CN202510075375.2A patent/CN120093940A/zh active Pending
- 2022-01-25 CN CN202280003045.7A patent/CN115279417B/zh active Active
- 2022-01-25 MX MX2023008895A patent/MX2023008895A/es unknown
- 2022-01-25 KR KR1020237020432A patent/KR20230145038A/ko active Pending
- 2022-01-25 AU AU2022220512A patent/AU2022220512A1/en active Pending
- 2022-01-25 CN CN202411408470.1A patent/CN119504997A/zh active Pending
- 2022-01-25 WO PCT/CN2022/073822 patent/WO2022170971A1/zh not_active Ceased
- 2022-01-25 CA CA3206117A patent/CA3206117A1/en active Pending
- 2022-01-25 US US18/256,836 patent/US20240108745A1/en active Pending
- 2022-01-25 EP EP22752132.5A patent/EP4257154A4/en active Pending
- 2022-01-25 TW TW111103218A patent/TW202241521A/zh unknown
- 2022-01-25 JP JP2023540154A patent/JP2024508081A/ja active Pending
- 2022-01-25 CN CN202411408513.6A patent/CN119564878A/zh active Pending
- 2022-01-25 CN CN202510075563.5A patent/CN120093942A/zh active Pending
- 2022-01-25 CN CN202510075338.1A patent/CN120097999A/zh active Pending
-
2023
- 2023-07-27 IL IL304804A patent/IL304804A/en unknown
-
2026
- 2026-07-17 AU AU2026206227A patent/AU2026206227A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA3206117A1 (en) | 2022-08-18 |
| CN119564878A (zh) | 2025-03-07 |
| AU2022220512A9 (en) | 2024-10-24 |
| CN115279417B (zh) | 2025-01-03 |
| CN115279417A (zh) | 2022-11-01 |
| KR20230145038A (ko) | 2023-10-17 |
| CN120093940A (zh) | 2025-06-06 |
| CN120097999A (zh) | 2025-06-06 |
| TW202241521A (zh) | 2022-11-01 |
| EP4257154A4 (en) | 2026-04-22 |
| MX2023008895A (es) | 2023-08-09 |
| AU2026206227A1 (en) | 2026-08-06 |
| IL304804A (en) | 2023-09-01 |
| CN120093942A (zh) | 2025-06-06 |
| WO2022170971A1 (zh) | 2022-08-18 |
| CN119504997A (zh) | 2025-02-25 |
| EP4257154A1 (en) | 2023-10-11 |
| US20240108745A1 (en) | 2024-04-04 |
| JP2024508081A (ja) | 2024-02-22 |
| CN120093941A (zh) | 2025-06-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP4257154A1 (en) | Bioactive substance conjugate, preparation method therefor and use thereof | |
| AU2020291014B2 (en) | Aminobenzazepine compounds, immunoconjugates, and uses thereof | |
| EP4552654A1 (en) | Antibody-drug conjugate, and preparation method therefor and use thereof | |
| EP4471063A1 (en) | Antibody against her3, conjugate and use thereof | |
| AU2018236272B2 (en) | Benzazepine compounds, conjugates, and uses thereof | |
| US11185594B2 (en) | (Anti-HER2 antibody)-drug conjugate | |
| CA3225120A1 (en) | Linkers, drug linkers and conjugates thereof and methods of using the same | |
| CN117398474A (zh) | 生物活性偶联物及其制备方法和用途 | |
| CA3119956A1 (en) | Anti-cdh6 antibody-pyrrolobenzodiazepine derivative conjugate | |
| AU2023403987A1 (en) | Antibody-drug conjugate, preparation method therefor, and use thereof | |
| AU2023350248A1 (en) | Benzazepine derivative, conjugate containing same, and use thereof | |
| HK40097827A (en) | Bioactive substance conjugate, preparation method therefor and use thereof | |
| HK40120401A (en) | Antibody against her3, conjugate and use thereof | |
| HK40079580A (en) | Bioactive substance conjugate, preparation method therefor and use thereof | |
| TW202408590A (zh) | 抗體藥物偶聯物及其製備方法和用途 | |
| HK40121296A (en) | Bioactive conjugate, and preparation method therefor and use thereof | |
| HK40079580B (en) | Bioactive substance conjugate, preparation method therefor and use thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| SREP | Specification republished |